At USP, we have a tremendous opportunity to advance quality and improve pharmaceutical supply chains to help reduce shortages and unacceptable risks to health.
Rockville, MD (PRWEB) April 27, 2015
Jesse L. Goodman, M.D., M.P.H., has been elected President of the 2015–2020 United States Pharmacopeial Convention (USP) at the recently concluded Convention Meeting in Washington, D.C. Dr. Goodman is Professor of Medicine at Georgetown University and the Director of its Center on Medical Product Access, Safety and Stewardship (COMPASS).
As USP President, a volunteer position, Dr. Goodman will preside at the 2020 USP Convention Meeting. He will be a voting member, ex officio, of the Board of Trustees and serve on the Board’s Executive Committee. He also will appoint members to the committees of the Convention and serve as Chair of the Council of the Convention.
“Making progress on complex problems—from drug and vaccine shortages, to emergencies like Ebola—requires partnerships across private and public sectors and multiple disciplines,” said Goodman. “At USP, we have a tremendous opportunity to advance quality and improve pharmaceutical supply chains to help reduce shortages and unacceptable risks to health. I look forward to learning from and working with USP members and partners, including regulatory agencies, public health professionals, industry, academics and practitioners, to further advance USP’s impact, both in the U.S. and globally.”
“The talent and experience Dr. Goodman brings to USP will be critical in helping fulfill its mission,” said Dr. Ronald T. Piervincenzi, Chief Executive Officer of USP. “As the pharmaceutical and healthcare landscapes continue on more globalized and complex paths, strong leadership and vision will be needed to guide USP through this time of change and growth for our organization. We are honored and privileged to have Dr. Goodman in this important leadership role at USP.”
Prior to joining Georgetown University, Dr. Goodman served as the U.S. Food and Drug Administration’s Chief Scientist leading cross-cutting scientific efforts including public health preparedness and medical countermeasures. Before that, Dr. Goodman directed the FDA Center for Biologics Evaluation and Research, supporting innovative regulatory approaches and spearheading unique public-private efforts. Previously, as Senior Advisor to the FDA Commissioner, he started the U.S. Task Force on Antimicrobial Resistance (AMR), developing the first U.S. AMR Action Plan. Prior to joining the FDA, Dr. Goodman was Chief of Infectious Diseases at the University of Minnesota. An advisor on global health, he helped develop the World Health Organization (WHO) Global Vaccine Action Plan and serves on WHO’s Ebola Vaccine Advisory Group.
Dr. Goodman is a graduate of Harvard University and received his M.D. from Albert Einstein College of Medicine and postdoctoral training at the University of Pennsylvania and at UCLA, where he was Chief Resident. He has been elected to the Institute of Medicine of the National Academy of Sciences.